Clinical trial underway for new monoclonal
antibody daclizumab

Click here to view or print this bulletin in its original format.

Medical Update Memo
February 24, 2006

An international multi-centre clinical trial is underway to test the safety and effectiveness of daclizumab compared with inactive placebo. Investigators – including study sites in Canada – are enrolling 270 participants who meet the study criteria, which includes currently taking one of the beta interferon therapies.

About daclizumab: This agent is a laboratory-created monoclonal antibody that blocks the activity of a key immune activator in MS. A small study involving 19 people with relapsing-remitting or secondary-progressive MS conducted by Dr. John Rose and colleagues at the University of Utah found the therapy resulted in stability (nine participants) or improvement (10).

Clinical trial criteria: To be eligible for the study, participants must be 18-55 years old, have definite MS, be taking one of the beta interferon therapies and have experienced a relapse or MRI-detected disease activity within nine months prior to screening.

For more information, call the study enrolment centre at 1 800 772-0482 (English only) or go to the study website: www.choicestudy.com (English only)

ASK MS Information System Code: 1.4.1.12.2w

National Research Department
National Communications & Government Relations Department

Disclaimer
The Multiple Sclerosis Society of Canada is an independent, voluntary health agency and does not approve, endorse or recommend any specific product or therapy but provides information to assist individuals in making their own decisions.